Scientists have developed a method to reprogram cancer-fighting immune cells directly inside the body, potentially eliminating the need for complex lab-based manufacturing. Early results show rapid ...
Results from the phase 3 CLL17 trial (NCT04608318) are helping clarify the ongoing debate over continuous vs fixed-duration therapy in frontline chronic lymphocytic leukemia (CLL) ...
With promise to slow aging and cure some types of cancer, a new gene therapy presents cost and access hurdles for CT patients ...
Researchers developed a chip-based platform, “μPharma,” that rapidly predicts drug response through AI analysis for children ...
Curis, a biotechnology company dedicated to delivering innovative cancer treatments, has made significant strides in its mission to improve the lives of patients with lymphoma and leukemia. In their ...
A new form of CAR T kills leukemia, multiple myeloma, and sarcoma in mice, opening the door to a future off-the-shelf cancer ...
Continued Advancement of Pivotal Phase 3 REGAL Trial of Galinpepimut-S (GPS) in Acute Myeloid Leukemia (AML) - Final Analysis upon Reaching 80 ...
Cuba’s government granted NBC News rare access inside the Institute of Hematology and Immunology, a research facility in the ...
Miracle Trial Preliminary Blinded CRc Rate of 40% in First 30 Patients Suggests Encouraging Early Results in Relapsed/Refractory AMLHOUSTON, ...
Henry Repeating Arms has produced a limited-edition series of Golden Boy Silver rifles to help fund treatment for wildland ...
The sound of a bell ringing marked a life-changing moment for one local family Wednesday morning. Chloe Bennethum, the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results